| Comparing methods for estimation of heterogeneous treatment effects using observational data from health care databases T Wendling, K Jung, A Callahan, A Schuler, NH Shah, B Gallego Statistics in medicine 37 (23), 3309-3324, 2018 | 129 | 2018 |
| Development and validation of a simple reversed-phase HPLC method for the determination of camptothecin in animal organs following administration in solid lipid nanoparticles SM Martins, T Wendling, VMF Gonçalves, B Sarmento, DC Ferreira Journal of Chromatography B 880, 100-107, 2012 | 44 | 2012 |
| Development and validation of a methotrexate adherence assay J Bluett, I Riba-Garcia, SMM Verstappen, T Wendling, K Ogungbenro, ... Annals of the Rheumatic Diseases 78 (9), 1192-1197, 2019 | 24 | 2019 |
| Application of a Bayesian approach to physiological modelling of mavoglurant population pharmacokinetics T Wendling, S Dumitras, K Ogungbenro, L Aarons Journal of pharmacokinetics and pharmacodynamics 42, 639-657, 2015 | 23 | 2015 |
| Model-based evaluation of the impact of formulation and food intake on the complex oral absorption of mavoglurant in healthy subjects T Wendling, K Ogungbenro, E Pigeolet, S Dumitras, R Woessner, ... Pharmaceutical research 32, 1764-1778, 2015 | 21 | 2015 |
| Modelling of atorvastatin pharmacokinetics and the identification of the effect of a BCRP polymorphism in the Japanese population N Tsamandouras, Y Guo, T Wendling, S Hall, A Galetin, L Aarons Pharmacogenetics and Genomics 27 (1), 27-38, 2017 | 20 | 2017 |
| Reduction of a whole-body physiologically based pharmacokinetic model to stabilise the Bayesian analysis of clinical data T Wendling, N Tsamandouras, S Dumitras, E Pigeolet, K Ogungbenro, ... The AAPS journal 18, 196-209, 2016 | 19 | 2016 |
| Incorporation of stochastic variability in mechanistic population pharmacokinetic models: handling the physiological constraints using normal transformations N Tsamandouras, T Wendling, A Rostami-Hodjegan, A Galetin, L Aarons Journal of pharmacokinetics and pharmacodynamics 42, 349-373, 2015 | 15 | 2015 |
| Predicting survival of pancreatic cancer patients treated with gemcitabine using longitudinal tumour size data T Wendling, H Mistry, K Ogungbenro, L Aarons Cancer chemotherapy and pharmacology 77, 927-938, 2016 | 12 | 2016 |
| Hierarchical mechanistic modelling of clinical pharmacokinetic data T Wendling PQDT-UK & Ireland, 2016 | 1 | 2016 |
| A HPLC-SRM-MS based method for the detection of adherence to low-dose oral methotrexate J Bluett, T Wendling, K Ogungbenro, I Riba-Garcia, R Unwin, ... Arthritis and Rheumatology 67 (S10), 1652, 2015 | 1 | 2015 |
| Application of a Bayesian population approach to physiological modelling of mavoglurant pharmacokinetics T Wendling, S Dumitras, R Woessner, E Pigeolet, K Ogungbenro, ... Journal of Pharmacokinetics and Pharmacodynamics, 2015 | | 2015 |
| Supplementary material for the manuscript:“Modelling of atorvastatin pharmacokinetics and the identification of the effect of a BCRP polymorphism in the Japanese population” N Tsamandouras, Y Guo, T Wendling, S Hall, A Galetin, L Aarons | | |
| Population Approach Group Europe Population Approach Group Europe R Keizer | | |
Nikolaos Tsamandouras, PhDPfizer, Clinical Pharmacology & PharmacometricsAdresse e-mail validée de pfizer.com
